The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
MicroRNA-21: A novel therapeutic target in human cancer
Open accessAbstract
Resistance to anticancer agents is the major clinical obstacle to the successful treatment of cancer, yet the mechanisms underlying drug resistance have not been fully characterized. MicroRNAs (miRNAs) are endogenous, small (19-25 nucleotides in length) noncoding RNAs, which function by base pairing with messenger RNAs, thereby regulating protein expression. Emerging evidence shows that alteration of miRNAs is involved in cancer initiation and progression. MiR-21 is a miRNA that is overexpressed in most tumor types, and acts as an oncogene by targeting many tumor suppressor genes related to proliferation, apoptosis, and invasion. In vivo and in vitro studies suggest that miR-21 may serve as a diagnostic and prognostic marker for human malignancies. More recently, studies have identified an important role for miR-21 in anticancer drug resistance. Here, we review the mechanisms underlying miR-21-mediated chemoresistance and the potential use of miR-21 as a novel molecular target for cancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051
Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., Kudrolli, T. A., Yegnasubramanian, S., Luo, J., Rodriguez, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1448 · Cited by 416
Cited by
MicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049
Regulatory Mechanism of MicroRNA Expression in Cancer
Ali Syeda, Z., Langden, S. S. S., Munkhzul, C., Lee, M., & Song, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051723 · Cited by 995
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Wang, X., He, Y., Mackowiak, B., & Gao, B. (2021) · Gut · doi:10.1136/gutjnl-2020-322526 · Cited by 495
Emerging role of microRNA-21 in cancer
Feng, Y.-H., & Tsao, C.-J. (2016) · Biomedical Reports · doi:10.3892/br.2016.747 · Cited by 454
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes
Zhong, X., Chung, A. C. K., Chen, H. Y., Dong, Y., Meng, X. M., Li, R., Yang, W., Hou, F. F., & Lan, H. Y. (2013) · Diabetologia · doi:10.1007/s00125-012-2804-x · Cited by 355
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
Non-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Liu, Z.-L., Wang, H., Liu, J., & Wang, Z.-X. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1443-3 · Cited by 320
Self-citationBaumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
MicroRNA control of epithelial–mesenchymal transition and metastasis
Zhang, J., & Ma, L. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9368-6 · Cited by 273
Lajer, C. B., Garnæs, E., Friis-Hansen, L., Norrild, B., Therkildsen, M. H., Glud, M., Rossing, M., Lajer, H., Svane, D., Skotte, L., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.109 · Cited by 256
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
Leone, E., Morelli, E., Di Martino, M. T., Amodio, N., Foresta, U., Gullà, A., Rossi, M., Neri, A., Giordano, A., Munshi, N. C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3325 · Cited by 219
Targeting miR-21 for the Therapy of Pancreatic Cancer
Sicard, F., Gayral, M., Lulka, H., Buscail, L., & Cordelier, P. (2013) · Molecular Therapy · doi:10.1038/mt.2013.35 · Cited by 217
Synthetic circular RNA functions as a miR-21 sponge to suppress gastric carcinoma cell proliferation
Liu, X., Abraham, J. M., Cheng, Y., Wang, Z., Wang, Z., Zhang, G., Ashktorab, H., Smoot, D. T., Cole, R. N., Boronina, T. N., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.09.010 · Cited by 212
Self-citationMicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications
Strubberg, A. M., & Madison, B. B. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.027441 · Cited by 147
Interplay between miRNAs and host genes and their role in cancer
Liu, B., Shyr, Y., Cai, J., & Liu, Q. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz002 · Cited by 137
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
Han, Z., Chen, F., Ge, X., Tan, J., Lei, P., & Zhang, J. (2014) · Brain Research · doi:10.1016/j.brainres.2014.07.045 · Cited by 128
MicroRNA Dysregulation in the Spinal Cord following Traumatic Injury
Yunta, M., Nieto-Díaz, M., Esteban, F. J., Caballero-López, M., Navarro-Ruíz, R., Reigada, D., Pita-Thomas, D. W., Águila, Á. D., Muñoz-Galdeano, T., & Maza, R. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034534 · Cited by 122
Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway
Echevarría-Vargas, I. M., Valiyeva, F., & Vivas-Mejía, P. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097094 · Cited by 118
Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection
Kura, B., Kalocayova, B., Devaux, Y., & Bartekova, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030700 · Cited by 106
Verma, P., Ghosh, A., Ray, M., & Sarkar, S. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200310091719 · Cited by 41
Fu, Y., Zhen, J., & Lu, Z. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3643 · Cited by 39
“miR-21 plays a key role in human tumor progression and is considered an onco-miR (Pan et al., 2010).”
Metadata
- Authors
- Pan, X., Wang, Z.-X., & Wang, R.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2010-12-15
- Volume
- 10
- Issue
- 12
- Pages
- 1224-1232
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2088672733
- Cited by
- 322
- References
- 3
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.